Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 25;13(2):178.
doi: 10.3390/v13020178.

Phage Display Technology as a Powerful Platform for Antibody Drug Discovery

Kazuya Nagano  1   2 , Yasuo Tsutsumi  1   2   3
Affiliations
Review

Phage Display Technology as a Powerful Platform for Antibody Drug Discovery

Kazuya Nagano et al. Viruses. .

Abstract

Antibody drugs with a high affinity and specificity are effective and safe for intractable diseases, such as cancers and autoimmune diseases. Furthermore, they have played a central role in drug discovery, currently accounting for eight of the top 20 pharmaceutical products worldwide by sales. Forty years ago, clinical trials on antibody drugs that were thought to be a magic bullet failed, partly due to the immunogenicity of monoclonal antibodies produced in mice. The recent breakthrough in antibody drugs is largely because of the contribution of phage display technology. Here, we reviewed the importance of phage display technology as a powerful platform for antibody drug discovery from various perspectives, such as the development of human monoclonal antibodies, affinity enhancement of monoclonal antibodies, and the identification of therapeutic targets for antibody drugs.

Keywords: antibody drugs; phage antibody library; phage display system.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of different types of antibody formats displayed on the phages.
Figure 2
Figure 2
Flow chart outlining the sequence of events from construction of phage antibody libraries to generation of monoclonal antibodies with high affinity for antigens and low immunogenicity.
Figure 3
Figure 3
Schematic illustration of the antibody proteomics system. (1) Candidate proteins are detected using two-dimensional differential in-gel electrophoresis (2D-DIGE) and (2) identified by mass spectrometry analysis (MSA). Simultaneously, (3) monoclonal antibodies against all the proteins identified by 2D-DIGE are produced using a phage antibody library. Finally, (4) the proteins are validated as biomarkers and therapeutic targets using tissue microarray (TMA). Therefore, using this technology, the candidate proteins can be comprehensively validated, and the most useful proteins can be selected.
See this image and copyright information in PMC

References

    1. Smith G.P. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228:1315–1317. doi: 10.1126/science.4001944. - DOI - PubMed
    1. Widersten M., Mannervik B. Glutathione transferases with novel active sites isolated by phage display from a library of random mutants. J. Mol. Biol. 1995;250:115–122. doi: 10.1006/jmbi.1995.0362. - DOI - PubMed
    1. Jiang B., Liu W., Qu H., Meng L., Song S., Ouyang T., Shou C. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2. J. Biol. Chem. 2005;280:4656–4662. doi: 10.1074/jbc.M411047200. - DOI - PubMed
    1. Mukai Y., Sugita T., Yamato T., Yamanada N., Shibata H., Imai S., Abe Y., Nagano K., Nomura T., Tsutsumi Y., et al. Creation of novel Protein Transduction Domain (PTD) mutants by a phage display-based high-throughput screening system. Biol. Pharm. Bull. 2006;29:1570–1574. doi: 10.1248/bpb.29.1570. - DOI - PubMed
    1. Shibata H., Yoshioka Y., Ohkawa A., Minowa K., Mukai Y., Abe Y., Taniai M., Nomura T., Kayamuro H., Nabeshi H., et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J. Biol. Chem. 2008;283:998–1007. doi: 10.1074/jbc.M707933200. - DOI - PubMed

MeSH terms